SAN DIEGO — Use of metformin may offer some atherosclerosis protection for patients with type 1 diabetes but does not appear to improve glycemic control, new data suggest.
Findings from the double-blind, placebo-controlled Reducing with Metformin Vascular Adverse Lesions (REMOVAL) trial were